- Home
- IGC vs ANTX Comparison
IGC vs ANTX Comparison
Compare IGC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- ANTX
- Stock Information
- Founded
- IGC 2005
- ANTX 2017
- Country
- IGC United States
- ANTX United States
- Employees
- IGC N/A
- ANTX N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- IGC Health Care
- ANTX Health Care
- Exchange
- IGC Nasdaq
- ANTX Nasdaq
- Market Cap
- IGC 26.9M
- ANTX 31.9M
- IPO Year
- IGC N/A
- ANTX 2022
- Fundamental
- Price
- IGC $0.35
- ANTX $1.23
- Analyst Decision
- IGC Strong Buy
- ANTX Hold
- Analyst Count
- IGC 2
- ANTX 5
- Target Price
- IGC $3.63
- ANTX $3.50
- AVG Volume (30 Days)
- IGC 222.5K
- ANTX 918.3K
- Earning Date
- IGC 11-12-2024
- ANTX 11-13-2024
- Dividend Yield
- IGC N/A
- ANTX N/A
- EPS Growth
- IGC N/A
- ANTX N/A
- EPS
- IGC N/A
- ANTX N/A
- Revenue
- IGC $1,183,000.00
- ANTX N/A
- Revenue This Year
- IGC N/A
- ANTX N/A
- Revenue Next Year
- IGC $13.57
- ANTX N/A
- P/E Ratio
- IGC N/A
- ANTX N/A
- Revenue Growth
- IGC N/A
- ANTX N/A
- 52 Week Low
- IGC $0.25
- ANTX $0.87
- 52 Week High
- IGC $0.91
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- IGC 42.76
- ANTX 65.23
- Support Level
- IGC $0.33
- ANTX $0.98
- Resistance Level
- IGC $0.42
- ANTX $1.04
- Average True Range (ATR)
- IGC 0.02
- ANTX 0.07
- MACD
- IGC -0.00
- ANTX 0.02
- Stochastic Oscillator
- IGC 32.14
- ANTX 52.58
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.